Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
Status:
Completed
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end
of the operation. Our goal is to compare the half-dose use of sugammadex for reversing
residual blockade after administration of neostigmine and atropine to the routine use of
reversal medication.
Phase:
Phase 4
Details
Lead Sponsor:
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital